GSK, Prosensa treat first patient in DMD trial
GSK2402968, an antisense oligonucleotide which induces exon skipping of exon 51, is currently in late stage development for DMD. The study which is designed to evaluate the safety
South Korea-based Alteogen has signed an exclusive licensing deal worth up to $365m with a global pharmaceutical company, granting worldwide rights to develop and commercialise a subcutaneous biologic product using its Hybrozyme technology.
Pharmstandard is a Russian pharmaceutical company focused in R&D and production of the medicinal products. Pharmstandard operates three modern pharmaceutical manufacturing facilities: JSC Pharmstandard-Leksredstva in Kursk, JSC Pharmstandard-UfaVITA